Asmacure Ltée is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary molecules that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company’s lead development compound, ASM-024, with its novel mechanism of action, has demonstrated the capabilities of anti-inflammation, bronchoprotection, and smooth muscle relaxation in pre-clinical asthma models.
ASM-024 delivered as a solution for nebulization achieved proof of concept in the treatment of patients with asthma in a phase 2 clinical trial. Asmacure has advanced ASM-024 into the clinic for the treatment of moderate asthma and COPD with a dry powder for inhalation (DPI) formulation.
The DPI is a preferred dosage form for many patients with pulmonary airway diseases and should allow ASM-024 to be delivered with greater lung deposition yielding the potential for a lower and more optimal dose.
The need for new pulmonary disease treatments with novel mechanisms :
Researching a novel approach : click here
The role of nicotinic and muscarinic receptors : click here